Euroapi (EAPIP) Stock Overview
Develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
EAPIP Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Euroapi S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.16 |
| 52 Week High | €3.88 |
| 52 Week Low | €2.65 |
| Beta | 0.70 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -81.90% |
| 5 Year Change | n/a |
| Change since IPO | -78.19% |
Recent News & Updates
Recent updates
Shareholder Returns
| EAPIP | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0% | 10.9% | 2.0% |
| 1Y | n/a | 5.0% | 13.2% |
Return vs Industry: Insufficient data to determine how EAPIP performed against the UK Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how EAPIP performed against the UK Market.
Price Volatility
| EAPIP volatility | |
|---|---|
| EAPIP Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 7.5% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.8% |
| 10% least volatile stocks in GB Market | 2.4% |
Stable Share Price: EAPIP's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine EAPIP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 3,187 | David Seignolle | www.euroapi.com/en |
Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally. The company offers contract development manufacturing organization for different classes of tides that uses solid phase chemistry; particle engineering; microbial fermentation; small molecules synthesis; prostaglandins; steroids and hormones; and opiates and controlled substances. It provides their products to pharmaceutical, generic drug manufacturers, animal health product manufacturers, consumer health, nutrition and cosmetic product companies, biotech companies, and distribution companies, as well as contract development and manufacturing organization.
Euroapi S.A. Fundamentals Summary
| EAPIP fundamental statistics | |
|---|---|
| Market cap | €312.68m |
| Earnings (TTM) | -€124.30m |
| Revenue (TTM) | €882.80m |
Is EAPIP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EAPIP income statement (TTM) | |
|---|---|
| Revenue | €882.80m |
| Cost of Revenue | €761.80m |
| Gross Profit | €121.00m |
| Other Expenses | €245.30m |
| Earnings | -€124.30m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Mar 03, 2026
| Earnings per share (EPS) | -1.31 |
| Gross Margin | 13.71% |
| Net Profit Margin | -14.08% |
| Debt/Equity Ratio | 5.3% |
How did EAPIP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/06 20:56 |
| End of Day Share Price | 2025/08/25 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Euroapi S.A. is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Patrick Andrew Wood | BofA Global Research |
| Falko Friedrichs | Deutsche Bank |
| Fynn Scherzler | Deutsche Bank |